Literature DB >> 1628126

Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation.

K Pauksen1, V Duraj, P Ljungman, J Sjölin, G Oberg, G Lönnerholm, E Fridell, B Smedmyr, B Simonsson.   

Abstract

Humoral immunity to measles, rubella and mumps was studied in 63, 36 and 16 patients 1, 2 and 3 years, respectively after autologous bone marrow transplantation (ABMT). Serologic examination was performed using antibody-ELISA. One year after ABMT, 7/57 patients (12%) who were seropositive to measles before ABMT, became seronegative, 8/44 (18%) to rubella and 3/51 (6%) to mumps. Among patients who were retested at 2 and 3 years, three more patients became seronegative to measles, one to rubella, and three to mumps. Nine of 12 children who had previously been immunized against measles were seropositive before ABMT, 3/7 to rubella and 5/7 to mumps, respectively. After ABMT, 5/9 became seronegative to measles, none to rubella and 2/5 to mumps. Six seronegative children were immunized with a live trivalent attenuated measles, mumps, and rubella vaccine 1 to 2 years after ABMT. Two children seroconverted to measles, six to rubella, and four to mumps. No side effects were observed. Most adult patients who have had the diseases of measles, rubella, or mumps naturally remain seropositive, while children who have been immunized commonly lose their immunity after ABMT.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1628126

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

Review 1.  Immunizations in solid organ and hematopoeitic stem cell transplant patients: A comprehensive review.

Authors:  Arnaud G L'Huillier; Deepali Kumar
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Immunization for bone marrow transplant recipients.

Authors:  B Lynn Johnston; John M Conly
Journal:  Can J Infect Dis       Date:  2002-11

3.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

4.  Live virus vaccines in transplantation: friend or foe?

Authors:  Charlotte M Verolet; Klara M Posfay-Barbe
Journal:  Curr Infect Dis Rep       Date:  2015-04       Impact factor: 3.725

5.  Association between graft source and response to live-attenuated vaccination in pediatric hematopoietic stem cell transplantation recipients: a single-center retrospective study.

Authors:  Takako Suzuki; Jun-Ichi Kawada; Eri Nishikawa; Yuka Torii; Kazuhiro Horiba; Suguru Takeuchi; Toshihiko Okumura; Hideki Muramatsu; Yoshiyuki Takahashi; Yoshinori Ito
Journal:  Bone Marrow Transplant       Date:  2020-03-20       Impact factor: 5.483

6.  Measles vaccination of special risk groups.

Authors:  Vassiliki Papaevangelou
Journal:  Hum Vaccin Immunother       Date:  2021-11-17       Impact factor: 3.452

7.  Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction.

Authors:  V Hammarström; K Pauksen; J Azinge; G Oberg; P Ljungman
Journal:  Support Care Cancer       Date:  1993-07       Impact factor: 3.603

Review 8.  Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party.

Authors:  Maria Teresa Cencioni; Angela Genchi; Gavin Brittain; Thushan I de Silva; Basil Sharrack; John Andrew Snowden; Tobias Alexander; Raffaella Greco; Paolo A Muraro
Journal:  Front Immunol       Date:  2022-02-01       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.